FibroBiologics, Inc. (FBLG)
NCM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
FBLG Proxy Statement outlines director elections and key corporate approvals
# 📜 What This Document Is 📰 This document is a Preliminary Proxy Statement (PRE 14A), which is a critical filing that tells stockholders what they will be asked to vote on at the upcoming Annual Meeting of Stockholders. Simply put, it is a "how-to guide" and a "here's what we want you to approve"
FBLG achieves Nasdaq listing compliance, stabilizing its market presence
# 📰 What This Document Is 📄 This document is a filing called an 8-K, which is a critical regulatory notice to the market. It means that FibroBiologics, Inc. is announcing a major, material event that happened *after* the company's regular financial reporting. Instead of a detailed quarterly repor
SEC filings
All filings →Insider trades
All insider trades →FibroBiologics, Inc. has no reported insider trades in the last 90 days.